Abstract:BackgroundMiddle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to combat MERS-CoV infection. On the basis of our previous work in development of peptide fusion inhibitors against HIV and SARS-CoV, and the crystal structure of the six-helix-bundle core of the MERS-CoV spike protein, we identified a peptide derived from the MERS-CoV S protein S2 subunit HR2 domain (HR2P) with a potent inhibitory activity against S-protein-mediated cell–cell fusion. Here, we tested an HR2P analogue with improved pharmaceutical properties, HR2P-M2, for its inhibitory activity against MERS-CoV infection in vitro and in vivo (appendix).MethodsWe assessed the anti-MERS-CoV activities of HR2P-M2 in vitro with pseudotyped MERS-CoVs in cell culture and in vivo with live MERS-CoVs in hDPP4-transgenic mice. The activities of HR2P-M2 to form six-helix bundles with HR1 peptides and to block fusion core formation between HR1 and HR2 peptides were studied using methods such as circular dichroism, N-PAGE, and FN-PAGE.FindingsHR2P-M2 was highly effective in blockade of cell–cell fusion mediated by MERS-CoV S proteins and inhibition of infection by MERS pseudoviruses expressing MERS-CoV S protein with or without mutation in the HR1 region, with IC50 (the concentration causing 50% inhibition) less than 0·7 μM. HR2P-M2 bound to the HR1 peptide to form stable six-helix bundles and blocked fusion core formation between the HR1 and HR2 peptides. Intranasal administration of HR2P-M2 before viral challenge fully protected hDPP4-transgenic mice (n=5) from MERS-CoV infection, whereas all the untreated mice (n=5) died 8 days after viral challenge.InterpretationOur findings suggest that the HR2P-M2 peptide merits further development as an effective and safe anti-MERS-CoV drug, alone or in combination with other antiviral drugs, to treat MERS-CoV-infected patients and to prevent the disease in high-risk populations, including health-care workers and family members of patients.FundingThis work was supported by grants from the National Science Fund of China (81173098 and 81361120378 to SJ, 81373456 to LL), the National 973 Program of China (2012CB519001 to SJ), and the US National Biocontainment Laboratories Operations Support (5UC7AI094660-05 to C-TKT). The funders had no role in interpretation of the findings and writing of this abstract.

Co-expression of Human Complement Regulatory Proteins DAF and MCP with an IRES-mediated Dicistronic Mammalian Vector Enhances Their Cell Protective Effects.

Co-Expression of the Complement Regulatory Proteins Human Daf and Cd59 with an Ires-Mediated Dicistronic Mammalian Vector Enhances Their Cell Protective Effects

Cooperation Between Human Daf and Cd59 in Protecting Cells from Human Complement-Mediated Lysis

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro

NF-κB and Enhancer-binding CREB Protein Scaffolded by CREB-binding Protein (cbp)/p300 Proteins Regulate CD59 Protein Expression to Protect Cells from Complement Attack*

Blockade of the C5a-C5aR Axis Alleviates Lung Damage in Hdpp4-Transgenic Mice Infected with MERS-CoV

Combining A Fusion Inhibitory Peptide Targeting The Mers-Cov S2 Protein Hr1 Domain And A Neutralizing Antibody Specific For The S1 Protein Receptor-Binding Domain (Rbd) Showed Potent Synergism Against Pseudotyped Mers-Cov With Or Without Mutations In Rbd

Construction and identification of a recombinant adenoviral vector expressing murine dendritic cell-associ-atedC-type lectin-1

Intranasally Administered Peptidic Viral Fusion Inhibitor Protected Hdpp4 Transgenic Mice from MERS-CoV Infection

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.

CG001, a C3b-targeted complement inhibitor blocks three complement pathways: development and preclinical evaluation

M Cell-Targeting Strategy Facilitates Mucosal Immune Response and Enhances Protection Against CVB3-induced Viral Myocarditis Elicited by Chitosan-Dna Vaccine.

Advances in membrane cofactor protein

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

Triple-fusion protein (TRIFU): a potent, targeted, enzyme-like inhibitor of all three complement activation pathways

New function of a well‐known promoter: Enhancer activity of minimal CMV promoter enables efficient dual‐cassette transgene expression

Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities

A novel host restriction factor MRPS6 mediates the inhibition of PDCoV infection in HIEC-6 cells